Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 187 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PARP Inhibitor Clear all

Conditions: Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Prostate Cancer, Prostate Cancer
Interventions: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq; Drug · Device · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Pembrolizumab, Olaparib, Cisplatin, IMRT (intensity modulated radiation therapy); Biological · Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 4
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Chapel Hill, North Carolina + 1 more

Conditions: Metastatic Melanoma
Interventions: Niraparib; Drug
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Interventions: Olaparib, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Gilbert, Arizona • Orange, California • Stanford, California + 14 more

Conditions: Solid Tumors
Interventions: CEP-9722; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Aurora, Colorado • Detroit, Michigan • St Louis, Missouri + 1 more

Conditions: Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: talazoparib, Physician's-Choice; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 207
States / cities: Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more

Conditions: Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Interventions: AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II; Drug
Lead sponsor: AtlasMedx, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more

Conditions: Solid Tumors
Interventions: Tislelizumab, Pamiparib; Biological · Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Brain Metastases
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Adenocarcinoma
Interventions: Niraparib + Nivolumab, Niraparib + Ipilimumab; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer, Castration-resistant Prostate Cancer
Interventions: Olaparib, Vitamin C; Drug · Dietary Supplement
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
Interventions: Niraparib, Irinotecan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Small Cell Lung Cancer
Interventions: NMS-03305293, Temozolomide; Drug
Lead sponsor: Nerviano Medical Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee

Conditions: Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 51
States / cities: Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more

Conditions: Acute Myeloid Leukemia
Interventions: Talazoparib, Topotecan, Gemcitabine; Drug
Lead sponsor: Norman J. Lacayo; Other
Eligibility: Up to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 9
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 6 more

Conditions: Triple Negative Breast Cancer
Interventions: gemcitabine plus carboplatin plus BSI-201; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Stanford, California • Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Interventions: MOMA-313, Olaparib; Drug
Lead sponsor: MOMA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Goodyear, Arizona • La Jolla, California • San Francisco, California + 8 more

Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
Interventions: Talazoparib, Temozolomide; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 6
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more

Conditions: Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
Interventions: EIS-12656, PARPi, Trastuzumab deruxtecan, Darolutamide (BAY 1841788); Drug
Lead sponsor: Eisbach Bio GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Shreveport, Louisiana • Durham, North Carolina • Houston, Texas + 1 more

Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 453
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 305 more

Conditions: Pancreatic Cancer
Interventions: Niraparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Acute Myocardial Infarction
Interventions: INO-1001; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 10
States / cities: Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more

Conditions: Prostate Cancer Metastatic
Interventions: [18F]FluorThanatrace; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

Pembrolizumab Plus Olaparib in LA-HNSCC

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Niraparib in Patients With Pancreatic Cancer

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

FTT PET/CT in Metastatic Prostate Cancer